Literature DB >> 18227191

Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes.

Dror Marchaim1, Shiri Navon-Venezia, Mitchell J Schwaber, Yehuda Carmeli.   

Abstract

The prevalence of isolation of imipenem-resistant Enterobacter (IRE) strains is rising, with potential serious consequences in terms of patients' outcomes and general care. The study objective was to define the various epidemiological aspects of the isolation of these strains in comparison to cases of isolation of imipenem-susceptible Enterobacter (ISE) strains. Molecular analysis of IRE strains included genotyping and defining the presence of carbapenemases. We conducted a matched retrospective case-control study of patients hospitalized from April 2003 to December 2006. Each IRE case was matched with an ISE case by age and source of isolation. A multivariate analysis using conditional logistic regression was performed to compare the two patient groups. There were 33 cases of IRE isolations during the study period. Twenty isolates were analyzed and found to belong to three distinct pulsotypes. Cell extracts of all of these isolates hydrolyzed imipenem. PCR and sequencing revealed that these isolates harbored a KPC-2 gene. In multivariate analysis, a high invasive-device score (P = 0.02) remained a predictor of IRE isolation. The mortality in the IRE group was 33%, compared to 9% among controls. Being an IRE case was significantly associated with increased mortality after controlling for confounders in a multivariate model (odds ratio, 8.3 +/- 8.6; 95% confidence interval, 1.07 to 64; P = 0.043). Resistance to imipenem due to bla(KPC-2) among Enterobacter isolates has occurred in several clones in Tel Aviv, affecting particularly patients with multiple invasive devices compared to ISE controls. IRE infections are associated with increased mortality. Enhanced measures to control the hospital spread of IRE are warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18227191      PMCID: PMC2292520          DOI: 10.1128/AAC.01103-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 2.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

3.  Identification of beta-lactamases by analytical isoelectric focusing: correlation with bacterial taxonomy.

Authors:  M Matthew; A M Harris
Journal:  J Gen Microbiol       Date:  1976-05

4.  Molecular epidemiology of infections due to Enterobacter aerogenes: identification of hospital outbreak-associated strains by molecular techniques.

Authors:  P R Georghiou; R J Hamill; C E Wright; J Versalovic; T Koeuth; D A Watson; J R Lupski
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

5.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy.

Authors:  J W Chow; M J Fine; D M Shlaes; J P Quinn; D C Hooper; M P Johnson; R Ramphal; M M Wagener; D K Miyashiro; V L Yu
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

Review 6.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

7.  Validation of a prognostic score in critically ill patients undergoing transport.

Authors:  J F Bion; S A Edlin; G Ramsay; S McCabe; I M Ledingham
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-17

8.  Molecular epidemiology of Enterobacter aerogenes acquisition: one-year prospective study in two intensive care units.

Authors:  A Davin-Regli; D Monnet; P Saux; C Bosi; R Charrel; A Barthelemy; C Bollet
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

9.  Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens.

Authors:  Mitchell J Schwaber; Sara E Cosgrove; Howard S Gold; Keith S Kaye; Yehuda Carmeli
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

10.  NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America.

Authors:  Sudha Pottumarthy; Ellen Smith Moland; Stefan Juretschko; Susan R Swanzy; Kenneth S Thomson; Thomas R Fritsche
Journal:  Emerg Infect Dis       Date:  2003-08       Impact factor: 6.883

View more
  68 in total

1.  Imported Klebsiella pneumoniae carbapenemase-producing K. pneumoniae clones in a Greek hospital: impact of infection control measures for restraining their dissemination.

Authors:  Aggeliki Poulou; Evangelia Voulgari; Georgia Vrioni; Grigorios Xidopoulos; Aris Pliagkos; Vassiliki Chatzipantazi; Fani Markou; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2012-05-30       Impact factor: 5.948

Review 2.  Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods.

Authors:  Roberto Viau; Karen M Frank; Michael R Jacobs; Brigid Wilson; Keith Kaye; Curtis J Donskey; Federico Perez; Andrea Endimiani; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

3.  In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.

Authors:  Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  First outbreak of KPC-3-producing Klebsiella pneumoniae (ST258) clinical isolates in a Mexican Medical Center.

Authors:  Patricia Rodríguez-Zulueta; Jesús Silva-Sánchez; Humberto Barrios; Javier Reyes-Mar; Francisco Vélez-Pérez; Sara Arroyo-Escalante; Luis Ochoa-Carrera; Gabriela Delgado-Sapien; María Del Rosario Morales-Espinoza; Elsa Tamayo-Legorreta; Rigoberto Hernández-Castro; Ulises Garza-Ramos
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

5.  Detection of carbapenemase-producing bacteria by using an ultra-performance liquid chromatography-tandem mass spectrometry method.

Authors:  Anne Carricajo; Paul O Verhoeven; Salim Guezzou; Nathalie Fonsale; Gerald Aubert
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

6.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 7.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States.

Authors:  Pia S Pannaraj; Jennifer Dien Bard; Chiara Cerini; Scott J Weissman
Journal:  Pediatr Infect Dis J       Date:  2015-01       Impact factor: 2.129

9.  Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.

Authors:  Jae H Hong; Cornelius J Clancy; Shaoji Cheng; Ryan K Shields; Liang Chen; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.

Authors:  Michael J Satlin; Stephen G Jenkins; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2014-01-23       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.